Development of PET agent for cardiac sympathetic nervous system / 中华核医学与分子影像杂志

ABSTRACT

Many cardiac sympathetic changes occur before clinical symptoms being found in heart disease.PET/CT imaging can sensitively detect abnormal cardiac sympathetic nerve function.The recent development of several 11 C and 18F labeled cardiac sympathetic imaging agents is reviewed in this paper.11C-meta-hydroxyephedrine (11 C-HED) and 6-18F-fluorodopamine (18F-FDA) have been comprehensively studied already.N-11C-CH3-dopamine (11C-MDA) and N-(3-bromo-4-(3-18F-fluoropropoxy)-benzyl)-guanidine (18F-LMI1195) are novel imaging agents with potential for clinical application.